Berkeley Capital Partners LLC lessened its position in shares of AstraZeneca plc (NYSE:AZN) by 18.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,861 shares of the company’s stock after selling 6,087 shares during the quarter. Berkeley Capital Partners LLC’s holdings in AstraZeneca were worth $1,063,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. NEXT Financial Group Inc acquired a new position in shares of AstraZeneca during the third quarter valued at $169,000. Bessemer Group Inc. lifted its stake in shares of AstraZeneca by 64.3% during the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after acquiring an additional 1,820 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca during the second quarter valued at $175,000. Tiverton Asset Management LLC acquired a new position in AstraZeneca in the second quarter valued at about $178,000. Finally, Huntington National Bank lifted its stake in AstraZeneca by 66.4% in the third quarter. Huntington National Bank now owns 5,345 shares of the company’s stock valued at $212,000 after buying an additional 2,132 shares during the period. 16.06% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Plc Astrazeneca bought 246,666 shares of the business’s stock in a transaction on Friday, September 28th. The shares were purchased at an average price of $15.00 per share, with a total value of $3,699,990.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
AZN has been the topic of several analyst reports. Zacks Investment Research raised AstraZeneca from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research note on Tuesday, October 9th. ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, July 28th. Wolfe Research initiated coverage on AstraZeneca in a research note on Tuesday, October 23rd. They issued an “outperform” rating on the stock. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, Guggenheim initiated coverage on AstraZeneca in a research note on Monday, October 8th. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $40.34.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Book Value Per Share – BVPS
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.